# Epacadostat and Pembrolizumab in Patients With GIST

> **NCT03291054** · PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 1 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Epacadostat

## Key facts

- **NCT ID:** NCT03291054
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-28
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-08-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study ended prematurely at the request of the funding sponsor.
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03291054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03291054, "Epacadostat and Pembrolizumab in Patients With GIST". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03291054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*